Jiangsu Kanion Pharmaceutical Co Ltd (600557) - Total Liabilities
Based on the latest financial reports, Jiangsu Kanion Pharmaceutical Co Ltd (600557) has total liabilities worth CN¥1.83 Billion CNY (≈ $267.42 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 600557 long-term investments to assets to see how much of total assets are deployed in long-term investments.
Jiangsu Kanion Pharmaceutical Co Ltd - Total Liabilities Trend (1999–2024)
This chart illustrates how Jiangsu Kanion Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Jiangsu Kanion Pharmaceutical Co Ltd balance sheet assets.
Jiangsu Kanion Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jiangsu Kanion Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Coretronic
TWO:5371
|
Taiwan | NT$27.69 Billion |
|
Zhejiang Hongchang Electrical Technology Co. Ltd.
SHE:301008
|
China | CN¥694.38 Million |
|
Baltic Classifieds Group PLC
LSE:BCG
|
UK | €95.38 Million |
|
STAAR Surgical Company
NASDAQ:STAA
|
USA | $109.81 Million |
|
Hangzhou MDK Opto Electronic Corp. Ltd. A
SHG:688079
|
China | CN¥1.92 Billion |
|
Dividend 15 Split Corp
TO:DFN
|
Canada | CA$1.68 Billion |
|
NATURENERGIE
SW:NEAG
|
Switzerland | CHF655.50 Million |
|
Piedmont Office Realty Trust Inc
NYSE:PDM
|
USA | $2.53 Billion |
Liability Composition Analysis (1999–2024)
This chart breaks down Jiangsu Kanion Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Jiangsu Kanion Pharmaceutical Co Ltd to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jiangsu Kanion Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jiangsu Kanion Pharmaceutical Co Ltd (1999–2024)
The table below shows the annual total liabilities of Jiangsu Kanion Pharmaceutical Co Ltd from 1999 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.20 Billion ≈ $322.17 Million |
+26.77% |
| 2023-12-31 | CN¥1.74 Billion ≈ $254.14 Million |
-6.72% |
| 2022-12-31 | CN¥1.86 Billion ≈ $272.44 Million |
+20.48% |
| 2021-12-31 | CN¥1.55 Billion ≈ $226.13 Million |
-13.76% |
| 2020-12-31 | CN¥1.79 Billion ≈ $262.19 Million |
-11.45% |
| 2019-12-31 | CN¥2.02 Billion ≈ $296.09 Million |
+18.28% |
| 2018-12-31 | CN¥1.71 Billion ≈ $250.33 Million |
-4.97% |
| 2017-12-31 | CN¥1.80 Billion ≈ $263.43 Million |
+18.10% |
| 2016-12-31 | CN¥1.52 Billion ≈ $223.05 Million |
+6.31% |
| 2015-12-31 | CN¥1.43 Billion ≈ $209.80 Million |
-10.32% |
| 2014-12-31 | CN¥1.60 Billion ≈ $233.94 Million |
+6.75% |
| 2013-12-31 | CN¥1.50 Billion ≈ $219.15 Million |
+1.59% |
| 2012-12-31 | CN¥1.47 Billion ≈ $215.73 Million |
+33.22% |
| 2011-12-31 | CN¥1.11 Billion ≈ $161.93 Million |
+48.90% |
| 2010-12-31 | CN¥743.19 Million ≈ $108.75 Million |
+102.38% |
| 2009-12-31 | CN¥367.23 Million ≈ $53.74 Million |
+3.20% |
| 2008-12-31 | CN¥355.85 Million ≈ $52.07 Million |
-24.90% |
| 2007-12-31 | CN¥473.81 Million ≈ $69.33 Million |
+6.91% |
| 2006-12-31 | CN¥443.19 Million ≈ $64.85 Million |
-16.79% |
| 2005-12-31 | CN¥532.62 Million ≈ $77.94 Million |
+43.61% |
| 2004-12-31 | CN¥370.88 Million ≈ $54.27 Million |
-8.10% |
| 2003-12-31 | CN¥403.56 Million ≈ $59.05 Million |
+335.38% |
| 2002-12-31 | CN¥92.69 Million ≈ $13.56 Million |
-10.54% |
| 2001-12-31 | CN¥103.61 Million ≈ $15.16 Million |
-12.87% |
| 2000-12-31 | CN¥118.92 Million ≈ $17.40 Million |
+4.46% |
| 1999-12-31 | CN¥113.84 Million ≈ $16.66 Million |
-- |
About Jiangsu Kanion Pharmaceutical Co Ltd
Jiangsu Kanion Pharmaceutical Co.,Ltd. researches and develops, produces, and sells Chinese medicines. It also offers medicines in the fields of anti-infections, orthopedics, gynecology, cardio and cerebrovascular, tonic-class, and others. In addition, the company provides herb extracts and formula granules, as well as OEM/ODM services. Jiangsu Kanion Pharmaceutical Co.,Ltd. was founded in 1975 a… Read more